 Aravive, Inc. ARAV, a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that the Company has been added to the Russell 2000 and Russell 3000 Indexes, effective June 29, 2020, as part of the 2020 Russell U.S. indexes reconstitution. Our inclusion in the Russell indexes reflects the meaningful progress we have made toward our goal of changing the treatment paradigm for people living with cancer, said Gail McIntyre, Ph.D., chief executive officer of Aravive. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. 